Search

Your search keyword '"Sehouli, Jalid"' showing total 2,529 results

Search Constraints

Start Over You searched for: Author "Sehouli, Jalid" Remove constraint Author: "Sehouli, Jalid"
2,529 results on '"Sehouli, Jalid"'

Search Results

1. Genome-wide association analyses of ovarian cancer patients undergoing primary debulking surgery identify candidate genes for residual disease

3. Dynamics of clonal hematopoiesis under DNA-damaging treatment in patients with ovarian cancer

6. AHRR and SFRP2 in primary versus recurrent high-grade serous ovarian carcinoma and their prognostic implication

9. Correction: Dynamics of clonal hematopoiesis under DNA-damaging treatment in patients with ovarian cancer

11. Lurbinectedin in patients with pretreated endometrial cancer: results from a phase 2 basket clinical trial and exploratory translational study

12. Amyloid-like p53 as prognostic biomarker in serous ovarian cancer—a study of the OVCAD consortium

13. Pazopanib with Topotecan weekly for patients with platinum-resistant or intermediate-sensitive recurrent ovarian cancer: results of a multicentre, open label phase I/II study (TOPAZ)

17. High EVI1 and PARP1 expression as favourable prognostic markers in high-grade serous ovarian carcinoma

18. Ten recommendations for sarcoma surgery: consensus of the surgical societies based on the German S3 guideline “Adult Soft Tissue Sarcomas”

19. Self-reported exhaustion and a 4-item physical frailty index to predict the incidence of major complications after onco-geriatric surgery

20. Long-term follow-up of efficacy and safety of selinexor maintenance treatment in patients with TP53wt advanced or recurrent endometrial cancer: A subgroup analysis of the ENGOT-EN5/GOG-3055/SIENDO study

21. Hidden in plain sight – Survival consequences of baseline symptom burden in women with recurrent ovarian cancer

26. Pembrolizumab or placebo with chemoradiotherapy followed by pembrolizumab or placebo for newly diagnosed, high-risk, locally advanced cervical cancer (ENGOT-cx11/GOG-3047/KEYNOTE-A18): a randomised, double-blind, phase 3 clinical trial

27. Fibroblast Growth Factor Receptors and Ligands in Context of Bevacizumab Response in Ovarian Carcinoma: An Exploratory Analysis of AGO-OVAR11/ICON-7

28. Statement of the AGO Kommission Ovar, AGO Study Group, NOGGO, AGO Austria, Swiss AGO, BGOG, CEEGOG, GEICO, and SFOG regarding the use of hyperthermic intraperitoneal chemotherapy (HIPEC) in epithelial ovarian cancer

31. Cancer

34. Molecular determinants of clinical outcomes of pembrolizumab in recurrent ovarian cancer: Exploratory analysis of KEYNOTE-100

35. LRP1B—a prognostic marker in tubo-ovarian high-grade serous carcinoma

36. Impact of BRCA Mutation Status on Tumor Dissemination Pattern, Surgical Outcome and Patient Survival in Primary and Recurrent High-Grade Serous Ovarian Cancer: A Multicenter Retrospective Study by the Ovarian Cancer Therapy-Innovative Models Prolong Survival (OCTIPS) Consortium

39. Overall survival and patient-reported outcome results from the placebo-controlled randomized phase III IMagyn050/GOG 3015/ENGOT-OV39 trial of atezolizumab for newly diagnosed stage III/IV ovarian cancer

40. Increased expression of IDO1 is associated with improved survival and increased number of TILs in patients with high-grade serous ovarian cancer

41. Self-reported Exhaustion and a 4-item Physical Frailty Index to Predict the Incidence of Major Complications after Onco-Geriatric Surgery

44. Randomized phase II trial of farletuzumab plus chemotherapy versus placebo plus chemotherapy in low CA-125 platinum-sensitive ovarian cancer

46. Essential medicines for childhood cancer in Europe: a pan-European, systematic analysis by SIOPE

49. ENGOT-EN20/GOG-3083/XPORT-EC-042 – A phase III, randomized, placebo-controlled, double-blind, multicenter trial of selinexor in maintenance therapy after systemic therapy for patients with p53 wild-type, advanced, or recurrent endometrial carcinoma: rationale, methods, and trial design

50. Supplementary Figure S4 from Influence of Genomic Landscape on Cancer Immunotherapy for Newly Diagnosed Ovarian Cancer: Biomarker Analyses from the IMagyn050 Randomized Clinical Trial

Catalog

Books, media, physical & digital resources